Pharmaceutical Robots Market Research Report Information By Type (Traditional Robots, Articluated Robot, SCARA Robots, Delta/Parallel Robots, Cartesian Robots, Sual-arm Robots, Collaborative Tobots, Others) BY Application (Picking and Packaging, Pharmaceutical Drugs Inspection, Laboratory Applications) By End-User (Pharmacetical Companies, Research Laboratories) By Region (North America, Europe, Asia Pacific, Rest of the World) Forecast 2032

Global Pharmaceutical Robots Market Overview

Pharmaceutical Robots Market Size was valued at USD 305.45 Billion in 2023. The Global Pharmaceutical Robots industry is projected to grow from USD 318.73 Billion in 2024 to USD 357.46 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 10.12% during the forecast period (2024 - 2032).

Pharmaceutical robots are automated machines used in hospitals and pharmacies to deliver pharmaceuticals. They are often controlled by computer software and are designed to do duties such as pill counting, medicine mixing, and delivery to patients. 

Pharmaceutical manufacturing benefits from robotic systems include higher production flexibility, reduced production downtime, no personnel turnover, improved health and safety, better waste management, improved production output, and product quality, and cheaper operating costs.

Astellas Pharma Inc. (TSE:4503, President and CEO: Naoki Okamura, "Astellas") announced that it had signed a memorandum of understanding with YASKAWA Electric Corporation (YASKAWA). This is in order to begin talks on the development of a new cell therapy ecosystem created by blending drugs as well as robotics technologies. Although non-binding and signaling no commitment, this memorandum will result in future discussions between the two firms. The complexity of manufacturing products presents considerable impediments to the commercialization of cell therapy. These include large-scale capital expenditures for process development activities and technology transfer among contract manufacturers as well as establishing full scale manufacturing facilities for commercial purposes. Unfortunately, startups and academia cannot independently normalize cell therapy.

In March 2024, Dr. Alex Oshmyansky the co-founder and CEO of The Mark Cuban Cost Plus Drug Company announced that his company would start making its own medicines in Texas this week while speaking at one of White House roundtables where they discussed how to lower healthcare costs on Monday. The first products from this corporation which Oshmyansky began together with Mark Cuban who is an American billionaire would be EpiPens’ epinephrine used in order to increase blood pressure and norepinephrine used to maintain blood pressure for patients being intensive care unit (ICU) admitted in hospitals. Coy about exact dates concerning the “this week” startup on these two medications but said that pediatric oncology drugs should be launched “shortly after”.

In October 2023, JVM –an affiliate firm of Hanmi Science - independently developed AI-based drug dispensing machine including robotic arm, successfully introduced a cutting-edge automated medicine dispensing machine into Europe’s market. Into Netherlands JVM announced on 13th that it had contracted with Brocacef-a European company operating factory like big dispensing pharmacies for MENITH-an automatic dispenser machine with articulated robotic arm. This deal empowers JVM to start moving from its initial market entry products toward high-end mass production in Europe. In view of this, it is expected that majority of overseas factory type dispensing pharmacies are likely to switch to MENITH units, capable of achieving a much higher pharmacy workflow due to the fact that they repackage prescription drugs into large geographical areas.

The necessity for automation in manufacturing plants, as well as the high expenses of drug discovery, are driving the growth of the pharmaceutical robots market. With the increasing demand for new medicines and medications, the majority of pharmaceutical companies are focusing on increasing the production of automated equipment and robots to meet the rising demand for high speed and precision. Traditional robots, such as cartesian robots, SCARA robots, and articulated robots, will increase rapidly in tandem with collaborative robotics.

The rising demand for pharmaceutical robots can be traced back to two major factors: the high costs of drug research and the increasing need for automation in production facilities. Companies in the pharmaceutical industry are responding to the increased demand for new medicines and pharmaceuticals by investing heavily in the development of automated equipment and robots. Traditional robots will proliferate at the same time as collaborative robotics, and this includes cartesian robots, SCARA robots, and articulated robots.

Robotics for automating processes in clinical trials, drug development, and laboratories are in great demand due to the rising need for automation in manufacturing units and the high expenses of new drug research. The introduction of highly sophisticated robotic devices by leading corporations has also contributed to the market's meteoric rise. Automation and robots have become increasingly popular in the pharmaceutical business in response to escalating demands for precision, production, and shorter turnaround times. There are also several time-saving advantages to employing robots in the pharmaceutical industry. The need for rigorous drug inspection is growing around the globe, especially in the pharmaceutical industry.

March 2023: Stäubli Robotics plans to show how its robots may improve product safety and efficacy as well as assist firms grow production in March 2023. Stäubli has been increasing its range, providing new levels of adaptability, safety, and performance in response to the growing difficulties in the pharmaceutical and biotechnology industries brought on by tighter laws and increasing market expectations. Introduced in 2022, the Stericlean+ series of robots is made specifically for use in sterile environments like isolation wards. New FDA-compliant dynamic sealings and a coating on all surfaces contribute to its increased ease of cleaning.

Report Overview

This MRFR's market research report delivers a comprehensive analysis of key trends in the global pharmaceutical robots market. It includes a detailed discussion on the historical trends, current market status, growth opportunities and challenges backed by fact-based feedbacks. The primary types of pharmaceutical robots that are covered in the report are traditional and collaborative robots. For opportunity analysis, the application areas of pharmaceutical robots have been assessed in the report, which include picking and packaging, pharmaceutical drugs inspection and laboratory applications. The end-users discussed in the report are pharmaceutical companies and research laboratories. the sub-markets covered in the report are profiled under four major regions that include North America, Europe, Asia Pacific and the rest of the world.

Report Coverage

MRFR's report on the global pharmaceutical robots market covers historical market trends, current market dynamics, market valuation by segmentation and region, country-level breakdown for market segments, competitive landscape, key player's market share analysis and supply chain analysis.

Companies Covered

• Kawasaki Heavy Industries Ltd. (Japan)


• FANUC Corporation (Japan)


• KUKA AG (Germany)


• Universal Robots A/S (Denmark)


• Mitsubishi Electric Corporation (Japan)


• ABB Ltd. (Switzerland)


• Denso Corporation (Japan)


• Seiko Epson Corporation (Japan)


• Yaskawa Electric Corporation (Japan)


• Marchesini Group S.p.A (Italy)


• Shibuya Corporation (Japan).

Research Methodology

MRFR leverages its industry expertise for the deliverance of qualitative and quantitative analysis of current market trends, growth opportunities, latest developments, challenges and consumer landscape. Data analytics through primary and secondary research processes is carried out for providing comprehensive market insights. Surveys and first-hand interviews are conducted for collection of primary data which is then verified by using secondary research process where paid databases, SEC filings, white papers, research publications and other credible sources available in public domain are utilized as references. The combination of data triangulation technique and top-down and bottom-up approaches ensures the deliverance of accurate market foresight by gauging the market dynamics.

Recent Development

Multiply Labs, a robotics business, has partnered with Thermo Fisher Scientific and Charles River Pharmaceuticals to automate cell treatment production. Multiply Labs is armed itself with two more pieces of industry-leading technology in order to automate manual elements of the cell therapy production process. The new kit arrives a little over a year after the robotics firm announced a consortium aiming at developing a robotic manufacturing system for mass-producing cell treatments.

Engel, a producer of injection molding machines and automation, has purchased a majority stake in TMA Automation, a Polish company. TMA provides automation solutions for in-mold labeling, palletizing, quality inspection, and more. Engel will be able to deliver highly integrated and completely automated injection molding production cells from a single supplier after acquiring TMA. While TMA will focus on automating in-mold labeling processes in the medium-performance area, Engel will continue to collaborate with its long-standing partner, IML Automation, for the high-performance segment.

March 2023: The MultiDose powder dosing device was developed by UK-based Labman Automation and collaborative robotics (cobots) firm Universal robotics in March 2023. Because of the MultiDose method, pharmaceutical companies may rapidly release drugs for testing and bring them to market. This automated, extremely precise tool for dispensing solids will cut the time spent on each experiment by technicians from six hours to just a few minutes. 

August 2023: Knightscope, Inc., a market leader in autonomous security robots and blue light emergency communication systems, has signed a 7-robot contract with a publicly traded biotechnology firm that creates and sells treatments for deadly diseases. The contract is set to begin in August 2023. One K5 Autonomous Security Robot ("ASR") will be deployed to monitor a four-story parking garage for the new customer, and a total of six K1-Tower ASRs will keep watch over the company's main entrances, open spaces, and parking lots. Knightscope's tools will ensure the safety of everyone working in this state-of-the-art facility dedicated to improving people's health, as well as the materials and ideas they're developing.

Pharmaceutical Robots Market Segmentation

For the scope of report, MRFR offers a comprehensive segmental analysis of the global pharmaceutical robots market

Pharmaceutical Robots Type Outlook

• Traditional Robots

-Articulated Robot

-SCARA Robots

-Delta/Parallel Robots

-Cartesian Robots

-Dual-arm Robots

-Others

• Collaborative Robots

Pharmaceutical Robots Application Outlook

• Picking and Packaging


• Pharmaceutical Drugs Inspection


• Laboratory Applications

Pharmaceutical Robots End-User Outlook

• Pharmaceutical Companies


• Research Laboratories

Pharmaceutical Robots Regional Outlook

• North America


• Europe


• Asia Pacific


• Rest of the World

Intended Audience

• Pharmaceutical manufacturing units


• Industrial robots manufacturers


• Market research and consulting firms


• Technology investors


• Distributors of industrial robots


• Community centers


• Government bodies/municipal corporations


• Venture capitalists


• Regulatory bodies


• Business research and consulting service providers